rs587777472
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3_ModeratePP5
The NM_015450.3(POT1):c.266A>G(p.Tyr89Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,456,418 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_015450.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POT1 | NM_015450.3 | c.266A>G | p.Tyr89Cys | missense_variant | 8/19 | ENST00000357628.8 | NP_056265.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POT1 | ENST00000357628.8 | c.266A>G | p.Tyr89Cys | missense_variant | 8/19 | 2 | NM_015450.3 | ENSP00000350249 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000408 AC: 1AN: 245188Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 132530
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1456418Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 724438
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Tumor predisposition syndrome 3 Pathogenic:1Uncertain:1
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 2014 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 11, 2021 | This variant is not present in population databases (ExAC no frequency). This sequence change replaces tyrosine with cysteine at codon 89 of the POT1 protein (p.Tyr89Cys). The tyrosine residue is moderately conserved and there is a large physicochemical difference between tyrosine and cysteine. This variant has been observed to segregate with cutaneous malignant melanoma in a family (PMID: 24686849). ClinVar contains an entry for this variant (Variation ID: 139520). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Experimental studies have shown that this missense change disrupts POT1 protein function (PMID: 24686849, 27869160). - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 14, 2021 | The p.Y89C variant (also known as c.266A>G), located in coding exon 4 of the POT1 gene, results from an A to G substitution at nucleotide position 266. The tyrosine at codon 89 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration has been identified in a family with cutaneous malignant melanoma and was shown to segregate with disease (Robles-Espinoza CD et al. Nat. Genet., 2014 May;46:478-481). Functional studies have indicated that the p.Y89C variant is deficient at telomere binding (Gu P et al. Oncogene, 2017 04;36:1939-1951, Robles-Espinoza CD et al. Nat. Genet., 2014 May;46:478-481), and is correlated with longer telomeres in affected individuals (Robles-Espinoza CD et al. Nat. Genet., 2014 May;46:478-481). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on internal structural analysis, Y89C changes DNA binding (Ambry internal data). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at